Prognostic Implications of the Expression of erbB2, Topoisomerase IIα and Thymidylate Synthase in Metastatic Gastric Cancer After Fluorouracil-based Therapy
Objective: This retrospective study aimed to ascertain the expression of erbB2 in relation to topoisomerase IIα (T2α) and thymidylate synthase (TS) markers in 30 consecutive metastatic gastric cancer patients with a specimen available for study. Methods: All patients had been entered on consecutive...
Saved in:
Published in | Japanese journal of clinical oncology Vol. 34; no. 12; pp. 727 - 732 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
01.12.2004
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective: This retrospective study aimed to ascertain the expression of erbB2 in relation to topoisomerase IIα (T2α) and thymidylate synthase (TS) markers in 30 consecutive metastatic gastric cancer patients with a specimen available for study. Methods: All patients had been entered on consecutive chemotherapeutic clinical trials that were all 5-fluorouracil based. The specimens were evaluated by fluorescence in situ hybridization to ascertain erbB2 and T2α gene amplification, and by immunohistochemical staining for T2α and TS protein expression. Results: erbB2 amplification was detected in 16.7% of specimens, with co-amplification of the T2α gene in 40%, and 44% had undetectable TS protein expression. Kaplan–Meier survival curves showed significantly prolonged overall survival in patients with erbB2 and T2α gene amplification, T2α protein overexpression and absence of TS protein expression (P = 0.0011, P = 0.0048, P = 0.0061 and P = 0.0267, respectively, by log rank test). There was a positive correlation between erbB2 amplification and T2α amplification, T2α protein overexpression, and a trend towards absence of TS expression (P = 0.0001, P = 0.003 and P = 0.066 by Fisher's exact test). Conclusion: High dose fluorouracil/leucovorin-based chemotherapy may have the potential to reverse the adverse effects resulting from erbB2 gene amplification in gastric cancer. |
---|---|
Bibliography: | istex:3A879342970C7CDCD86DE5CB4AE05CE51337B967 local:hyh137 ark:/67375/HXZ-841V6QGZ-T For reprints and all correspondence: Jacqueline M. Liu, Division of Cancer Research, National Health Research Institutes, c/o A191 Taipei-Veterans General Hospital, Shipai Rd, Sect 2, no. 201, Taipei, Taiwan. E-mail: jmliu@nhri.org.tw ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0368-2811 1465-3621 |
DOI: | 10.1093/jjco/hyh137 |